Dr. Lankford's professional interests include general radiation oncology, Intensity Modulated Radiation Therapy, 3D treatment planning, and prostate implants.
Dr. Lankford lives in Concord with his wife and two children. Originally from Maryland, he enjoys bicycling and the outdoors.
Cheverly, Maryland
Married, two children
Board Certified Radiation Oncology
as of June 1998
Diplomate - National Board of Medical Examiners (7/1/94)
Basic Cardiac Life Support - American Heart Association
North Carolina
South Carolina
Department of Radiation Oncology
University of Texas, M.D. Anderson Cancer Center
1515 Holcombe Boulevard, Box 97
Houston, TX 77030
Chief Resident (selected by faculty)
Fletcher Award for Research (First Place)
Gilbert H. Fletcher Society Essay Award
ASTRO Travel Awards (1996 & 1997)
M.D. Anderson Cancer Center Clinical Trainee Research Award
Selected for Berlex Oncology Foundation
Course Participation
M.D. Anderson Associates Steering Committee
Quality of Education Committee - Department of Radiation Oncology
Graduate Medical Education Committee
Clinical Operations Committee - Department of Radiation Oncology
Delegate - Residents' Section, Texas Radiological Society
Department of Medicine (Transitional)
York Hospital
1001 South George Street
P.O. Box 15198
York, Pennsylvania 17405-7198
Cancer Committee
Residents' Research Day Planning Committee
University of Maryland School of Medicine
655 W. Baltimore Street
Baltimore, Maryland 21201
*Includes 2 years of full-time research at the National Institutes of Health (see below).
Dean's Award for Excellence in Research
Howard Hughes Medical Institute - NIH Research Scholar
National Institutes of Health Intramural Research Training Award
University of Maryland Medical Student Research Day Awards (1990,91)
National Kidney Foundation of Maryland Mini-Grant
National Institutes of Health Summer Student Program Participant
Foundation for Advanced Education in the Sciences - Summer Student Grant
Maryland State Senatorial Scholarship Recipient (1987,88,91,92)
University of Maryland
College Park, Maryland 20742
Major: Biochemistry
Phi Sigma Biological Honor Society
Golden Key National Honor society
Alpha Lambda Delta Freshman Honor Society
Dean's List
Alpha Rho Chapter Recorder, Alpha Chi Sigma Professional Chemistry Fraternity
Student Health Advisory Board Member
Ultrasound-Guided Permanent Prostate Implants, University of South Florida,
H, Lee Mofitt Cancer Center, Tampa, Florida 33612
Berlex Oncology Foundation Epidemiology/Clinical Trial Design Course, Brewster, Massachusetts
American College of Radiology
American Society for the Therapeutic Radiology and Oncology, Junior Member
American Medical Association
M.D. Anderson Associates
M.D. Anderson Cancer Center Clinical Research training Award Recipient, Department of Radiobiology, M.D. Anderson Cancer Center, Houston, TX 77030.
Focus: Cell senescence as a predictor of late radiation toxicity using in vitro and in vivo assays.
Howard Hughes Medical Institute - National Institutes of Health Research Scholar, CBMB, NICHHD, National Institutes of Health, Bethesda, MD 20892
Mentor: Richard D. Klausner, MD (Director of the National Cancer Institute).
National Institutes of Health Intramural Research Training Award Recipient,LKEM, NHLBI, National Institutes of Health, Bethesda, MD 20892.
National Kidney Foundation of Maryland Mini-Grant Recipient, Department of Physiology, University of Maryland School of Medicine
Baltimore, MD 21201
Medical Student Research Participant, Department of Nephrology,
Walter Reed Army Institute of Research, Washington, DC 20307
American Society for Therapeutic Radiology and Oncology, Orlando, Fl.
Topic: In vitro irradiation of early-passage human fibroblasts induces senescence-Associated B-galactosidase activity
Meeting of the Texas Radiological Society, El Paso, TX.
Topic: PSA cancer volume as a prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy
American Society for therapeutic Radiology and Oncology, Los Angeles, CA
Topic: PSA cancer volume as a prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy
Gilbert H. Fletcher Society Annual Meeting, Williamsburg, VA
Topic: PSA cancer volume as a prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
American Society for Theraputic Radiology and Oncology, Miami. Fl 33014
Topic: PSA density as a prognostic factor for prostate cancer patients treated with radiotherapy.
1. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eschenbach AC, Geara FB: Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: An evaluation based on disease outcome. Cancer, 85: 1577-1585, 1999.
2. Liebross RA, Lankford SP, von Eschenbach AC, Zagars GK, Pollack A: Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage TIC prostate cancer treated with radiotherapy, Urology, 52: 647-652, 1998.
3. Lankford SP, Pollack A, Zagars GK: Prostate specific antigen cancer volume: A significant prognostic factor in cancer patients at intermediate risk of failing radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 38:327-333,1997.
4. Pollack A. Lankford SP, Zagars GK, Babaian RJ: Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer, 77: 1515-1523,1996.
5. Lankford SP, Pollack A, Zagars GZ: Radiotherapy for regionally localized hormone refractory prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 33: 907-912, 1995.
6. Lankford SP, Peters KL, Elser RC: Potential effects of age-specific reference ranges for prostate-specific antigen. European Urology, 27: 182-186, 1995.
7. Lankford SP, Cosson P, Bonifacino JS, Klausner RD: Transmembrane domain length affects charge-mediated retention and degradation of proteins within the endoplasmix reticulum, J. Biol, Chem., 268: 4814-4820, 1993.
8. Lankford SP, Chou C-L, Terada Y, Wall SM, Wade JB, Knepper MA: Regulation of collecting duct water permeability independent of cAMP-mediated AVP response. Amer. J. Physiol., 261: F554-566, 1991.
9. Cosson P, Lankford SP, Bonifacino JS, Klausner RD: Membrane protein association by potential intramembrane charge pairs [see comments], Nature, 351: 414-416,1991.
10. Atkins JL, Lankford SP: Changes in cytochrome oxidation in outer and inner stripes of the outer medulla, Amer, J, Physiol., 261: F849-857, 1991.
1. Lankford SP, Eifel PJ: Principles of Radiotherapy, in Pediatric Surgical Oncology, (ed, Andrassy, RJ), W.B. Saunders Company, Philadelphia, (in press).
2. Knepper nMA, Lankford SP, Terada Y: Renal tubular actions of ANF, Canadian Journal of Physiology and Pharmacology, 69: 1537-1545, 1991 (peer reviewed).
3. Flessner MF, Flamion B, Wright Chou C-L, Lankford S., Knepper MA: Review of: Comparative Physiology, RKH Kinne (Editor), Basel: Karger, 148 pp, 1989, Physiologist, October, 1990.
1. Lankford SP, Geara FB, Zagars GK, Pollack A: Transrectal ultrasound staging is an independent predictor of outcome following definitive radiotherapy for clinically localized prostate cancer, RSNA 1997.
2. Lankford SP, Geara FB, Brock WA: In vitro irradiation of early-passage fibroblasts induces senescence associated B-galactosidase activity, IJROBP 39:252, 1997.
3. Ha CS, Lankford SP, McLean RC, Kong JM, Fuller LM, Hess MA, Cabanillas F, Cox JD: Non-Hodgkin̰-s lymphoma of the Waldeyer̰-s ring (NHWR): Outcome for 110 patients with modem staging evaluation, IJROP 39: 252. 1997.
4. Lankford SP, Pollack A, Zagars GZ: PSA cancer volume: A significant prognostic factor in cancer patients at intermediate risk of failing radiotherapy, IJROP 36,:307, 1996.
5. Lankford SP, Peters KL, Elser RC: Potential effects of age-specific reference ranges for prostate-specific antigen.. Urol. Digest, June: 3-4, 1996.
6. Lankford SP, Pollack A, Zagars GK: PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy, IJROBP 32: 229, 1995.
7. Lankford SP, Chou C-L, Wade JB, Knepper MA: Control of osmotic water permeability in the rat inner medullary collecting duct by in vivo conditioning and vasopressin, ASN 676, 1990.
8. Atkins JL, Lankford SP: Changes in the oxidative state of cytochrome aa3 in the outer medulla (OM), Kidney Internat., 37: 476A, 1990.
9. Atkins JL, Lankford SP: High dose lasix transiently decreases blood flow in the outer medulla of the rat kidney, FASEBJ., 3: A1016, 1989.
